UBS analyst Luiz Carvalho downgrades Ecopetrol (NYSE:EC) from Buy to Neutral.
Unpacking Blueprint Medicines’ Ayvakit’s Bright Future: Insights From Latest Physician Survey On Sales Predictions
Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ: BPMC) from $65 to $66